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ABSTRACT - Purpose Achieving successful gene therapy requires delivery of a gene vector specifically to the 
targeted tissue with efficient expression and a good safety profile. The objective of this work was to develop, 
characterize and determine if a novel gemini surfactant-based lipoplex systems, modified with a cancer-targeting 
peptide p18-4, could serve this role. Methods The targeting peptide p18-4 was either chemically coupled to a 
gemini surfactant backbone or physically co-formulated with the lipoplexes. The influence of targeting ligand and 
formulation strategies on essential physicochemical properties of the lipoplexes was evaluated by dynamic light 
scattering and small angle X-ray scattering techniques. In vitro transfection activity and cellular toxicity of 
lipoplexes were assessed in a model human melanoma cell line. Results All lipoplexes zeta potential and particle 
size were optimal for cellular uptake and physical stability of the system. The lipoplexes adopted an inverted-
hexagonal lipid arrangement. The lipoplexes modified with the peptide showed no significant changes in 
physicochemical properties or lipoplex assembly. The modification of the lipoplexes with the targeting peptide 
significantly enhanced protein expression 2-6 fold compared to non-modified lipoplexes. In addition, p18-4 
modified lipoplexes significantly improved the safety of the lipoplexes. The ability of the p18-4 modified 
lipoplexes to selectively express the model protein was confirmed by using healthy human epidermal 
keratinocytes (HEKa). Conclusion The gemini surfactant-based lipoplexes modified with p18-4 peptide showed 
significantly higher efficiency and safety compared to the system that did not contain a cancer targeting peptide 
and provided evidence for their potential application to achieve targeted melanoma gene therapy.  
__________________________________________________________________________________________ 
 
INTRODUCTION  
 
In gene therapy, the efficiency of non-viral vectors 
depends on the successful delivery and expression of 
the exogenous genetic material into the targeted 
tissue, while causing minimum toxicity. For cancer 
gene therapy, non-viral gene delivery systems, which 
usually assemble as nano-sized particles, have the 
ability to non-specifically target the tumor (passive 
targeting) by an enhanced permeability and retention 
(EPR) effect, extravasation through the leaky 
vasculature surrounding the tumors and entrapment 
in the tumor mass.(1)  However, passive cancer 
targeting can be challenged by several factors 
including, but not limited to, the type of cancer, the 
heterogeneity of the tumor, blood supply, the 
interaction of the nanoparticles with the tumor and 
surrounding tissue, and the  
 
 
characteristics of the delivery system.(2, 3). On the 
other hand, cancer-specific targeting can be achieved 
by decorating the non-viral delivery system with 
cancer-specific ligands (active targeting). Such 
ligands can be a small-molecule moiety, protein, 
peptide or antibody (monoclonal antibody or 
fragment) that can specifically bind to an 
overexpressed enzyme, a receptor or a cancer-
specific antigen.(4) Such targeting can enhance the 
accumulation and 
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interaction of the ligand-modified nanoparticles 
which can improve their specific cellular 
internalization. As a result of specific uptake by 
cancer cells, off-target gene expression and toxicity 
can be avoided or at least minimized.(5). 
In cancer gene and drug delivery, different 
ligands have been explored for cancer specific 
targeting. These ligands include monoclonal 
antibodies such as trastuzumab to target HER2 
receptor in breast cancer, peptides such as arginyl-
glycyl-aspartic acid (RGD) to target overexpressed 
integrins, and small molecules such as folic acid to 
target the folate-binding protein.(3) Among different 
peptide ligands that have been explored for cancer 
targeting is p160, a linear dodecapeptide 
(VPWMEPAYQRFL) that was identified by phage 
display. It displayed a superior affinity for 
neuroblastoma cells and selective internalization in 
different breast cancer cell lines but not by normal 
umbilical vein/vascular endothelium cells 
(HUVEC).(6, 7) Based on the structure of p160, 
several linear decapeptides have been engineered 
with higher affinity to cancer cells (MDA-MB-435, 
and MCF-7) and better enzymatic stability.(8) 
Among these targeting peptides, p18-4 
(WxEAAYQrFL) [Figure 1] demonstrated the 
highest affinity and selectivity toward breast cancer 
cells and showed resistance to proteolytic 
degradation.(8) Decoration of liposomal-
doxorubicin with p18-4, as a cancer targeted drug 
delivery system, significantly improved the cellular 
uptake and cytotoxicity of doxorubicin selectivity in 
breast cancer.(9) In mice bearing MDA-MB-435 
tumour, the anti-cancer activity of the p18-4 
modified liposomal-doxorubicin was improved in 
comparison to the unmodified liposomal 
system.(10). 
Cationic gemini surfactants are cationic lipids 
that have been comprehensively evaluated and 
characterized for gene delivery.(11, 12) The 
versatility in the chemical structure of gemini 
surfactants makes it easy to produce highly efficient 
gene delivery systems with a good safety profile.(13-
15) For example, chemical modification in the basic 
structure of gemini surfactant by introducing amino 
acid substituents in the spacer region, producing 12-
7N(GK)-12 [Figure 1], has led to the production of 
an efficient biocompatible carrier. The applicability 
of topical gene delivery by cationic gemini 
surfactants was evaluated previously for dermal, 
vaginal and ocular applications.(13, 15, 16) The 
positive outcome provided evidence for the viability 
of using gemini surfactant-based lipoplexes for 
topical and transdermal gene delivery. Recently, we 
have reported the development and evaluation of an 
RGD-modified gemini surfactant lipoplex system 
that shows specificity to melanoma.(17) The 
introduction of the RGD moiety into the gemini 
surfactant structure enhanced the transfection 
activity by more than two fold compared to non-
modified lipoplexes.(17) The successful targeting of 
overexpressed integrin in a melanoma model 
provided evidence for the potential of using gemini 
surfactant-based lipoplexes for targeted cancer gene 
therapy. 
The objective of this work was to develop and 
characterize a novel cationic gemini surfactant-based 
lipoplex decorated with a specific cancer-targeting 
ligand (p18-4) and to evaluate its activity in a 
melanoma model. As well, we investigated the 
influence of the ligand modification on the essential 
physicochemical properties of the lipoplex system 
that govern the transfection activity. The specificity 
of the developed ligand-modified lipoplexes to target 
melanoma cells was also examined.  
 
MATERIALS & METHODS  
 
Materials  
N, N-diisopropylethylamine (DIPEA), 1-[bis 
(dimethylamino) methylene] -1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxidehexafluorophosphate (HATU), 
trifluoroacetic acid (TFA) and dimethyl sulfoxide 
(DMSO spectroscopy grade) were purchased from 
Sigma-Aldrich (Oakville, ON, Canada). Helper lipid 
1 , 2 dioleyl – sn – glycerol -
phosphatidylethanolamine (DOPE) was purchased 
from Avanti Polar Lipids, (Alabaster, AL, USA). 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) was purchased from Invitrogen 
Corporation (Grand Island, NY, USA). All solvents 
used were HPLC grade. 
 
Synthesis of gemini surfactant and peptide p18-4 
Synthesis and characterization of 12-7N(GK)-12 
gemini surfactant was reported previously.(18) 
Synthesis and characterization of linear peptide p18-
4 were described previously.(9)  
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a) 
 
b)  
 
c)  
 
Figure 1. Chemical structure of a) 12-7N(GK)-12, b) p18-4 peptide [p18-4] (WxEAAYQrFL) and c) 12-7N(p18-4)-12 
gemini surfactant [p18-4-G]  
NH3
+
NH
NH
NH
NH
NH
NH
NH
NH
NH
O
O O
O
O
O
O
O
O
OO
OO
OH NH
NHNH2
NH2O
NH
H
H
NH
NH
NH
NH
NH
NH
NH
NH
NH
NH
O
O O
O
O
O
O
O
O
OO
OO
OH NH
NHNH2
NH2O
NH
N
O
O
N+
N+
H
H
J Pharm Pharm Sci (www.cspsCanada.org) 21, 363 - 375, 2018 
 
 
 
366 
Synthesis of p18-4 modified gemini surfactant 
Peptide p18-4 on the chlorotrityl resin (with all side 
chain groups protected with Boc) was provided by 
Dr. Kaur’s group. (8) The synthesis of gemini 
surfactant backbone [3-(bis 3-(N-dodecyl-N,N-
dimethylamino)propyl)carbamoyl propanoic acid]2+ 
2Cl- was described previously.(19) In brief, under a 
N2 atmosphere using standard Schlenk techniques, a 
Schlenk flask equipped with a magnetic stir bar was 
charged with 3,3′ - iminobis ( N , N - 
dimethylpropylamine) (1.682 g, 8.989 mmol) and 
succinic anhydride (0.988 g, 9.873 mmol) in 15 mL 
of DMF to form a homogeneous solution. After 3 
days of stirring at ambient temperature, the reaction 
mixture was concentrated under vacuum to obtain an 
orange–yellow oily substance as the desired 
compound in quantitative yield. The compound was 
charged in a round-bottom flask with propanoic acid, 
(800.0 mg, 2.785 mmol) and 1-iodododecane (2.063 
g, 1.720 mL, 6.933 mmol) in DMF (20 mL) to form 
a yellow homogeneous solution. After 12 h of 
stirring at ambient temperature, the solvent was 
removed under vacuum and the residue washed 
several times with diethyl ether to remove the excess 
iodododecane. The sample was dried, yielding an 
orange oily substance that was dissolved in 10 mL of 
distilled water and 2.5 equivalents of Amberlite® 
IRA-400(Cl) (2.400 g, 6.933 mmol) was added to the 
solution. After stirring for 1 h, the Amberlite resin 
was removed by filtration and the residue washed 
with water. An orange, oily substance [ 3 - ( bis 3 - ( 
N – dodecyl – N , N 
dimethylamino)propyl)carbamoyl propanoic acid]2+ 
2Cl- was obtained in almost quantitative yield after 
removing excess water by freeze-drying. 
The gemini backbone was activated under a N2 
atmosphere in a round bottom flask, by reacting [ 3 - 
( bis 3 - ( N – dodecyl – N , N  dimethylamino ) 
propyl) carbamoyl propanoic acid]2+ 2Cl- (M.W. 
696.96 g/mol) with (O-(7-azabenzotriazol-1-yl)-N 
,N,N′,N′-tetramethyluronium hexafluorophosphate, 
HATU) (1.2 eq, M.W. 380.23 g/mol) and (N,N-
diisopropylethylamine, DIPEA) (2 eq, M.W. 129.25 
g/mol) in 10 mL of dry DMF at room temperature for 
15 min. 
For the coupling reaction, a solid phase peptide 
synthesis vessel [Medium Frit, GL 25 thread, Fritted 
Disc. Dia./25] (Chemglass Life Sciences, Vineland, 
NJ, USA) was charged with [p18-4]-chlorotrityl 
resin and activated gemini surfactant (1:5 moles) in 
10 mL of dry DMF. The coupling reaction was 
carried out for 3 days with continuous shaking and 
the solution removed from the vessel. The peptide-
gemini surfactant was cleaved from the resin and all 
protecting groups  were removed by using 50:50 
TFA/DCM, 5% TIPS at room temperature for 1 h (3 
times). The solution containing the modified gemini 
surfactant [p18-4-G] was collected and concentrated 
by rotary evaporation. The product was dissolved in 
50:50 (v/v) H2O/methanol and subjected to 3 cycles 
of cold acetone precipitation. The structure of the 
compound was confirmed by using an API QSTAR 
XL MS/MS hybrid QqToF tandem mass 
spectrometer equipped with an ESI source (Applied 
Biosystems Inc., CA, USA). ESI m/z 634 [M+H]3+ 
(expected m/z for [M+H]3+ is 634.758). 
 
Lipoplex formulations  
The construction of the plasmid pGThCMV.IFN-
GFP, used as a model for a robust plasmid, was 
described previously.(13) Plasmid DNA (coded as P 
in lipoplexes) was isolated and purified using 
QIAGEN Plasmid Giga Kit (Mississauga, ON, 
Canada) following the manufacturer’s protocol. 
Aqueous solutions of 3 mM gemini 
surfactant/peptide were used to prepare all lipoplex 
formulations evaluated in this work. 
Lipoplexes, Table 1, were formulated using a 
plasmid to gemini surfactant (phosphate/nitrogen) 
charge ratio of 1:10 in the presence of (DOPE) as a 
helper-lipid (coded as L in lipoplexes) creating 
plasmid/gemini surfactant/lipid lipoplexes [P.G.L], 
as described previously.(17) In brief, The DOPE 
were vesicles formed by sonication in 9.25% sucrose 
solution (pH 9) at a final concentration of 1 mM 
DOPE and filtered through Acrodisc® 0.45 µm 
syringe filters (Pall Gelman, Ann Arbor, MI). The 
[P/G] lipoplexes were prepared by mixing an aliquot 
of 200 µg pDNA aqueous solution with an 
appropriate amount of 3 mM gemini surfactant 
solution and incubated at room temperature for 20 
min. The [P.G.L] systems were prepared by mixing 
[P/G] lipoplexes with the DOPE vesicles at gemini 
surfactant to DOPE molar ratio of 1:10 and incubated 
at room temperature for 20 min. 
Peptide-modified lipoplex formulations were 
prepared in two different ways (as described 
earlier)(17). Briefly,10% of total non-modified 
gemini surfactant, 12-7N(GK)-12, was substituted 
by either peptide-modified gemini surfactant (p18-4-
G) in L2 and L3, (Table 1) or targeting peptide (p18-
4) in L4 and L5 (Table 1). 
 
Size and zeta potential measurements 
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Formulations (800 µL of each) were transferred into 
a special cuvette (DTS1061, Malvern Instruments, 
Worcestershire, UK) for size distribution and zeta-
potential measurements using a Zetasizer Nano ZS 
instrument (Malvern Instruments, Worcestershire, 
UK). Each sample was measured four times, and the 
results are expressed as an average ± standard 
deviation (SD) of a triplicate with corresponding 
polydispersity index (PDI) value (Table 2). 
 
Small-angle X-ray Scattering (SAXS) analysis 
Small-angle X-ray Scattering (SAXS) measurements 
were carried out at the Stanford Synchrotron 
Radiation Lightsource, Menlo Park, CA, California. 
Lipoplexes prepared as described above were 
concentrated (10x) by speed vacuuming at 35 ˚C.  A 
wavelength of 1.1271 Å (11KeV energy) was 
utilized. Samples were loaded in 1.5mm boron-rich 
glass capillaries (Charles Supper Company, USA). 
The scattered X-ray was detected on MAR225-HE 
(225 mm x 225 mm (3072 x 3072 pixels, pixel size 
73.24 μm) at 20 s exposure time and at a sample to 
detector distance of 1.1 m. The SAXS detector was 
calibrated with silver behenate. GSASII software 
was used to plot diffraction intensity versus 2θ 
(where θ is the diffraction angle) or q (scattering 
vector) by radial integration of the 2D patterns. 
 
Cell culture and in vitro transfection  
Human malignant melanoma (A375) cell line 
(ATCC® CRL-1619™) was cultured in Dulbecco's 
modified Eagle's medium (DMEM) supplemented 
with 10% fetal bovine serum and 1% antibiotic and 
incubated at 37 °C under an atmosphere of 5% 
CO2/95% air. Normal adult human epidermal 
keratinocyte cells (HEKa,C-005-5C, Cascade 
Biologics, Invitrogen), were grown on a T-75 Cell+ 
tissue culture flask (Sarstedt AG & Co.) in Medium 
154 (Gibco) supplemented with Human 
Keratinocyte Growth Supplement (HKGS, Gibco), 
10% fetal bovine serum and 1% antibiotic and 
incubated at 37 ˚C under an atmosphere of  5% 
CO2/95% air. 
The day prior to transfection, cells were seeded 
in 96-well tissue culture plates (BD Mississauga, 
ON, Canada) at a density of 1.5×104 cells/well for 
A375 and HEKa cell line at a density of 2×104 
 
Table 1. Preparation methods used for formulations evaluated.  All lipoplex systems prepared at 1:10 -/+ charge ratio and 
with helper lipid DOPE. P: pDNA, G:12-7N(GK)-12, L: DOPE,  p18-4-G : 12-7N( p18-4)-12,  p18-4:  p18-4 linear 
peptide. 
ID Preparation of Peptide modified lipoplex  Peptide/Peptide-gemini surfactant System produced  
L1 Conventional -- [P.G.L]  
L2 Chemical conjugation  10% 12-7N(p18-4)-12 Ch[P.G.p18-4-G.L] 
L3 Chemical conjugation  10% 12-7N(p18-4)-12 Ch[P.G.L].p18-4-G 
L4 Physical co-administration  10% p18-4 Ph[P.G.p18-4.L] 
L5 Physical co-administration  10% p18-4  Ph[P.G.L].p18-4 
L6 Chemical conjugation  100% 12-7N(p18-4)-12 Ch[P.G.p18-4-G.L] 
 
Table 2 Physiochemical properties (size and zeta potential) of different p18-4 modified lipoplexes formulations.  Size and zeta 
potential measurements: values are an average of n = 3 ± standard deviation (SD). The polydispersity (PDI) index is indicated 
for the size measurements as an average of three measurements ± STD. 
Preparation Method System produced Particle size (nm) ± SD PDI ± SD ζ-potential (mV) ± SD 
Conventional L1: [P.G.L] 157 ± (2.5) 0.251 ± (0.003) 22 ± (1.03) 
Chemical conjugation L2: Ch[P.G.p18-4-G.L] 144 ± (0.5) 0.296 ± (0.019) 19.5 ± (0.68) 
Chemical conjugation L3: Ch[P.G.L].p18-4-G 145 ± (2.4) 0.268 ± (0.002) 17.7 ± (1.45) 
Physical co-administration L4:  Ph[P.G.p18-4.L] 163 ± (2) 0.295 ± (0.014) 17 ± (2.32) 
Physical co-administration L5:  Ph[P.G.L].p18-4 174 ± (2.8) 0.364 ± (0.014) 15.2 ± (1.76) 
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cells/well in 96-well Cell+ tissue culture plate 
(Sarstedt AG & Co.). One hour before treatment, the 
media was replaced with non-supplemented media. 
Four wells per formulation were transfected with 
lipoplexes containing 0.2 µg pGThCMV.IFN-GFP 
plasmid/well. Lipofectamine Plus reagent 
(Invitrogen Life Technologies) was used according 
to the manufacturer’s protocol as a positive control 
with 0.2 µg pDNA/well. The 96-well tissue culture 
plates were then incubated at 37 °C under 5% CO2 
and 95% air. After 5 h, the media was removed and 
replaced with fresh supplemented media. 
Supernatants containing the secreted IFN-γ were 
collected at 24 and 48 h and replaced with fresh 
supplemented media. The collected supernatants 
were stored at -80 ˚C until further evaluated. 
 
Transfection activity (ELISA) 
Enzyme-linked immunosorbent assay (ELISA) was 
performed using Immulon 2 flat bottom 96-well 
plates (Greiner Labortechnik, Frickenhausen, 
Germany) following the BD Pharmingen protocol as 
previously described.(20) The concentration of 
expressed IFN-γ was calculated from a standard IFN-
γ curve using recombinant mouse IFN-γ standard 
(BD Pharmingen, BD Biosciences). 
 
Cytotoxicity assay 
MTT assay was used to evaluate the cellular toxicity 
of lipoplex systems in A375 and HEKa cell lines. A 
sterile solution of 4 mg/mL of MTT in PBS buffer 
was prepared. Cell lines were seeded on 96-well 
plates and transfected with lipoplexes (as described 
above). After 48 h, the cell lines were evaluated for 
cytotoxicity. The supplemented media was removed 
from the wells and replaced with 0.5 mg/mL MTT in 
supplemented media and incubated at 37 C in 5% 
CO2 and 95% air for 3 h. The supernatant was 
removed and each well washed with PBS. The purple 
formazan crystal that formed was dissolved in 
DMSO. Plates were incubated for 10 min at 37 C. 
Absorbance was measured at 580 nm using BioTek 
microplate reader (Bio-Tek Instruments, VT, USA). 
The cellular toxicity is expressed as a percentage of 
the non-transfected control cells ± SD. 
 
STATISTICAL ANALYSIS 
 
Statistical analyses were performed using SPSS 
software (Version 23.0). The results are expressed as 
the average of three independent experiments ± SD. 
One way analysis of variance (ANOVA, Dunnett's 
test) was used for statistical analyses. Significant 
differences were considered at p < 0.05 level. 
 
RESULTS 
 
The influence of p18-4-modification on the 
physicochemical characteristics of the lipoplexes  
Physicochemical properties that control the 
transfection activity and stability of lipoplexes are: 
particle size, surface charge and lipid assembly.(21, 
22) All lipoplexes formed particles with an average 
diameter of less than 180 nm. The average particle 
size of the non-modified lipoplexes (L1: [P.G.L]) 
was 157±2.5 nm (Table 2). Substitution of 10% of 
the parent gemini surfactant [12-7N(GK)-12] with 
the p18-4 conjugated gemini surfactant (p18-4-G)  
(L2: Ch[P.G.p18-4-G.L] and L3: Ch[P.G.L].p18-
4-G), caused a decrease in particle size to 144±0.5 
nm and 145±2.4, respectively. On the other hand, 
physical co-formulation of free p18-4 peptide with 
the lipoplex system caused an increase in the average 
size of the assembled nanoparticles with wide poly 
dispersity index values. For example, the addition of 
10% free p18-4 to the formed lipoplexes [P.L.G] 
(L5:  Ph[P.G.L].p18-4) caused an increase of 17 nm 
compared to non-modified lipoplexes (L1: [P.G.L]). 
Zeta potential measurements indicated that all 
lipoplexes carry an overall positive charge in the 
range of 22-15 mV. The substitution of 10% of non-
modified gemini surfactant (12-7N(GK)-12) with 
p18-4 gemini surfactant or free p18-4 peptide caused 
a decrease in zeta potential values. For example, 
L5:Ph[P.G.L].p18-4 showed the most significant 
reduction in zeta potential value of over 30% 
compared to the non-modified formulations 
(L1).(Table 2). 
The influence of the addition of the targeting 
peptide on the lipid phase arrangement and 
transitions of the lipoplexes was examined using 
SAXS [Figure 2]. All lipoplexes exhibited Bragg’s 
peaks with relative ratios of 1, √3 and √4, 
characteristic of an inverted hexagonal phase 
arrangement (HII).  The preparation method and 
presence or absence of targeting peptide-modified 
gemini surfactant or free targeting peptide in the 
lipoplex system did not cause any alteration in the 
lipid phase arrangement.  
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Figure 2. SAXS profile of [P.G.L] lipoplexes constructed at 1:10 -/+ charge ratio and with helper lipid DOPE (L) in all 
formulation. P: pDNA, G:12-7N(GK)-12, L: DOPE,  p18-4-G : 12-7N( p18-4)-12,  p18-4:  p18-4 linear peptide. 
 
 
In vitro evaluation 
Transfection efficiency and cellular toxicity 
To determine the optimum formulation strategy and 
amount of targeting peptide leading to the highest 
gene expression and lowest cellular toxicity, the 
transfection efficiency of the p18-4-modified 
lipoplexes was evaluated in human malignant 
melanoma (A375) cell line. Different concentrations 
of p18-4 modified gemini surfactant or free p18-4 (5, 
10, 15, 20% and 100% of the total amount of cationic 
lipid) were tested. The highest levels of gene 
expression (IFN-γ level by ELISA) were observed 
when 10% of p18-4 conjugated gemini surfactant 
(p18-4-G) or physical co-formulation of free p18-4 
was used [Figure 3 A]. ]. Lipoplexes formulated with 
100% of p18-4 conjugated gemini surfactant (p18-4-
G) showed a negligible level of gene expression 
[data not shown]. Incorporation of p18-4 modified 
gemini surfactant in the lipoplexes (either during the 
formation of lipoplexes, L:2 Ch[P.G.p18-4-G.L] , 
or after the formation of [P.L.G] lipoplexes, L3: 
Ch[P.G.L].p18-4-G) resulted in a 3-fold increase in 
IFN-γ level compared to standard non-targeting 
lipoplexes [P.G.L] [Figure 3 A]. The highest level of 
gene expression was obtained when lipoplexes were 
formulated by physical co-formulation of free p18-4 
(L4: Ph[P.G.p18-4.L] and L5: Ph[P.G.L].p18-4) 
with over a 6-fold increase being observed 
(1252±402 and 1152±328 pg IFN-γ/1.5×104 A375 
cells, respectively) [Figure 3 A].  
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Figure 3 (A) IFN-γ expression in A375 cells at 48-h post-treatment with lipoplexes constructed at 1:10 -/+ charge ratio. P: 
pDNA, G:12-7N(GK)-12, L: DOPE,  p18-4-G : 12-7N( p18-4)-12,  p18-4:  p18-4 linear peptide. (Ch) indicates lipoplexes 
chemically conjugated p18-4-G and (Ph) lipoplexes physically co-formulated with free p18-4. IFN-γ level determined by 
ELISA. Significant increases (* p<0.01, one-way ANOVA) in IFN- expression were observed in all p18-4 modified 
lipoplexes compared to non-modified lipoplexes (L1:[P.G.L]). (B) Cell viability in the same A375 cells after a 48-h treatment 
with p18-4-modified lipoplex formulations as determined by MTT assay. Cell viability values are given as % relative to non-
transfected cells. Four wells of each formulations were loaded on three different plates. The results are expressed as the mean 
of the three plates (n = 3). Bars represent standard deviation. * Indicates significance at p < 0.05 in comparison to standard 
formulation [P.G.L] (L1) 
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The influence of targeting peptide on the cellular 
toxicity of the lipoplexes was assessed by MTT assay 
[Figure 3 B]. 48-h post-transfection, the cell viability 
for non-modified lipoplexes L1:[P.G.L] was 
approximately 30% of the non-transfected cells 
[Figure 3 B]. Higher cell viability values were 
reported for lipoplexes formed with 10% chemically 
modified gemini surfactant (L2: Ch[P.G.p18-4-
G.L] and L3:Ch[P.G.L].p18-4-G). Physical co-
administration of free p18-4 with also showed an 
improvement in cellular viability compared to 
standard lipoplexes. Both p18-4 modified gemini 
surfactant (p18-4-G) and free targeting peptide (p18-
4) caused no or minimal toxicity to A375 cell line 
[Figure 3 B].  
 
Targeting efficiency  
The specificity of p18-4 modified lipoplexes to 
target melanoma cell lines was examined by 
transfecting primary human epidermal keratinocytes 
(HEKa) with standard lipoplexes, p18-4-G modified 
lipoplexes and lipoplexes co-formulated with free 
p18-4 (L1: [P/G/L], L2: Ch[P.G.p18-4-G.L] and 
L5: Ph[P.G.L].p18-4) [Figure 4 A]. The IFN-γ level 
after 48 h of transfection with L2: Ch[P.G.p18-4-
G.L] was similar to the level achieved by standard 
non-modified lipoplexes L1: [P/G/L]. Transfection 
with L5: Ph[P.G.L].p18-4 showed a slight, but not 
significant (p>0.05), increase in expressed IFN-γ 
level compared to standard [P.G.L] lipoplexes.  
MTT assay showed that targeting lipoplexes 
marginally enhanced the cellular viability in HEKa 
cell lines in comparison to standard [P.G.L] 
lipoplexes [Figure 4 B]. 
 
DISCUSSION  
 
Gene therapy for cancer is the most extensively 
explored amongst worldwide gene therapy clinical 
trials as 64.6% ( 1,590 trials) are investigating the 
potential of cancer gene therapy.(23) Creating an 
efficient and targeted gene delivery agent with 
effective therapeutic outcomes and good safety 
profile are required for successful clinical 
applications. Targeting tumors with lipid-based gene 
delivery systems can be achieved by chemically 
modifying the lipoplexes with tumor specific 
ligands.(24-26)  Gemini surfactant-based lipoplexes 
have been widely explored for gene delivery as they 
show good transfection efficiency and low cellular 
toxicity. The glycyl-lysine modified gemini 
surfactant used in this work, 12-7N(GK)-12, showed 
potential application as a non-invasive topical 
transfection agent for development of vaginal 
genetic vaccination.(15) In addition, by chemically 
modifying the 12-7N(GK)-12 with cRGD, to target 
over-expressed integrin receptor on melanoma, led 
to a significant increase of gene expression.(17) The 
ability of the RGD-modified lipoplexes to 
specifically target overexpressed α3/β1 integrin in 
melanoma was confirmed by using a positive 
competitor peptide (free RGD) and false-negative 
control peptide (RAD). As well, the RGD-modified 
gemini surfactant lipoplex did not enhance the 
transfection activity in normal human epidermal 
keratinocytes (HEKa), indicating the selectivity of 
the system toward the target.(17). 
The nature of the nano-carriers, such as 
modification of the chemical structure, and 
formulation strategies can influence the 
physicochemical properties of the lipoplex system, 
ultimately affecting the transfection efficiency. The 
size, shape and overall charge of the assembled 
lipoplexes can influence the physicochemical 
stability of the gene delivery system, its bio-
distribution, cellular uptake, gene expression, and 
cellular toxicity.(27) Gemini surfactant-based 
lipoplexes [P.L.G] can be internalized by 
mammalian cells via clathrin-mediated or caveolae-
mediated endocytosis pathways.(28) Modification of 
the chemical structure of the gemini surfactant 
influenced the shape of the lipoplexes and hence the 
main endocytosis uptake mechanism. For example, 
lipoplexes build with 12-7NH-12 gemini surfactant 
formed spherical-shape nanoparticles and were 
internalized mainly through a clathrin-mediated 
pathway. On the other hand, the modification of the 
gemini surfactant with a dipeptide moiety in the 
spacer region (i.e., 12-7N(GK)- 12) resulted in the 
formation of cylindrically shaped lipoplexes with 
larger particle size. This lipoplex system 
demonstrated pH sensitive characteristics and 
internalized the cells through caveolae-mediated 
endocytosis.(28) In the current work, co-formulation 
of lipoplex systems with free p18-4 (L4: 
Ph[P.G.p18-4.L] and L5: Ph[P.G.L].p18-4) 
showed the highest transfection efficiency with a 6-
fold increase in IFN-γ level compared to standard 
lipoplexes L1: [P.G.L] [Figure 3 A].  The lipoplexes 
assembled in larger nanoparticles (>150 nm) with a 
polymodal particle distribution compared to the 
standard lipoplexes (L1 [P.G.L]). 
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Figure 4 (A) IFN-γ expression in HEKA cell line at 48-h post-treatment with lipoplexes constructed at 1:10 -/+ charge ratio 
non-modified lipoplexes (L1:[P.G.L]), p18-4 chemically-conjugated lipoplexes (L2: Ch[P.G.p18-4-G.L]) and p18-4 peptide 
co-formulated with the lipoplexes (L5: Ph[P.G.L].p18-4). IFN-γ level determined by ELISA. (B) Cell viability of HEKA 
cells after a 48-h treatment with p18-4-modified lipoplex formulations as determined by MTT assay. Cell viability values are 
given as % relative to non-transfected cells. HEKA cell line is normal adult human epidermal keratinocyte cells which express 
normal level of integrins. No statistical significates was observed between non-modified lipoplexes and p18-4- modified 
lipoplexes. Four wells of each formulations were loaded on three different plates. The results are expressed as the mean of 
the three plates (n = 3). Bars represent standard deviation. 
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The heterogeneity of the size of these lipoplexes 
might have contributed to alterations in cellular 
uptake mechanisms, leading to an improvement in 
gene expression.(29) The modifications of the 
lipoplexes with targeting p18-4 peptide did not 
influence the supramolecular assembly, as all 
lipoplexes evaluated in this work arranged into 
inverted hexagonal structures (HII) [Figure 2]. This 
lipid phase arrangement is believed to contribute to 
the ability of the gemini based lipoplexes to interact 
with the cell membrane and facilitate the endosomal 
escape of the pDNA upon endocytosis.(13, 30)      
The use of peptide penetration enhancers has 
been widely explored to enhance the uptake of highly 
hydrophobic drugs and in gene delivery. For skin 
delivery, these peptides interact with skin proteins 
(namely keratins which are highly expressed in the 
skin) and enhance the transcellular uptake of drug 
molecules.(31) In normal skin conditions, keratins (a 
family of intermediate filaments) are the main 
structural proteins in the epidermis (mainly type II 
keratin KRT1 and KRT10 which mainly expressed 
in keratinocytes) and they show important role in 
maintaining skin integrity and in intracellular 
signaling pathways.(32) Mutations in keratins 
expressions are contributed to several skin hereditary 
disorders.(32, 33) In addition, several keratins 
showed distinctive expression (upregulated or 
downregulated) in certain cancers (such as lung, 
breast and skin cancers) and can be used for disease 
diagnosis and monitoring.(32) The linear 
dodecapeptide peptide p18-4 is able to bind 
preferably to cancerous cells (MDA-MB-435 and 
MCF-7) and internalized upon binding through 
endocytosis.(9, 10) In a MDA-MB-435 xenograft 
mouse model, p18-4 conjugated doxorubicin showed 
a 5-fold reduction in tumor size compared to the free 
drug.(9, 10) p18-4 specifically interacts with 
overexpressed KRT-1 in MDA-MB-435 and MCF-7 
cells.(34) In the current work, we evaluated the 
ability of p18-4 modified lipoplexes to target 
melanoma using a model cell line (A375) showing 
overexpression of keratins.(35, 36) The increase in 
gene expression by the p18-4 modified lipoplexes 
could be attributed to the specific interaction of p18-
4 with keratins and lead to improvement of cellular 
uptake of the lipoplexes and higher transfection 
activity [Figure 3 A]. We believe that the 
combination of heterogeneity of particle size and the 
availability of free p18-4 (not covalently bound to 
gemini surfactant) on the surface of the lipoplexes to 
interact with keratins in formulations L4 and L5 can 
explain the significant increase in transfection 
compared to non-modified (L1) and chemically 
modified lipoplexes (L2 and L3). The results of the 
control study (the transfection in HEKa cells which 
express a normal level of keratins) indicate the 
targeting specificity of the p18-4 modified lipoplexes 
to melanoma [Figure 4 A].    
 
CONCLUSIONS  
 
The results of this study show that gemini surfactant 
based lipoplexes modified with targeting peptide 
(p18-4) are able to deliver pDNA to melanoma and 
achieve higher gene expression with a good safety 
profile. The specificity of melanoma targeting for the 
lipoplexes was demonstrated by the higher gene 
expression compared to non-malignant 
keratinocytes. The ability of the targeted lipoplexes 
to interact specifically to overexpressed keratins in 
melanoma and to enhance their penetration into the 
tissue indicate the potential application of the system 
for topical gene delivery.  
 
ACKNOWLEDGEMENTS 
 
We thank the help of Dr. Jackson Chitanda with the 
synthesis of gemini surfactants. Funding was 
provided by the College of Pharmacy and Nutrition, 
Natural Sciences and Engineering Council of 
Canada. Scholarship W M-S was provided by Taibah 
University, Saudi Arabia. 
 
CONFLICT OF INTEREST 
 
The authors declare that they have no conflict of 
interest. 
 
REFERENCES  
 
1. Greish K. Enhanced permeability and retention (EPR) 
effect for anticancer nanomedicine drug targeting.  
Cancer Nanotechnology: Springer; 2010. p. 25-37. 
2. Danhier F, Feron O, Préat V. To exploit the tumor 
microenvironment: passive and active tumor 
targeting of nanocarriers for anti-cancer drug 
delivery. Journal of Controlled Release. 
2010;148(2):135-46. 
3. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. 
Cancer nanotechnology: the impact of passive and 
active targeting in the era of modern cancer biology. 
Advanced Drug Delivery Reviews. 2014;66:2-25. 
4. Steichen SD, Caldorera-Moore M, Peppas NA. A 
review of current nanoparticle and targeting moieties 
J Pharm Pharm Sci (www.cspsCanada.org) 21, 363 - 375, 2018 
 
 
 
374 
for the delivery of cancer therapeutics. European 
Journal of Pharmaceutical Sciences. 2013;48(3):416-
27. 
5. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, 
Tsourkas A. Multifunctional nanoparticles: cost 
versus benefit of adding targeting and imaging 
capabilities. Science. 2012;338(6109):903-10. 
6. Zhang J, Spring H, Schwab M. Neuroblastoma tumor 
cell-binding peptides identified through random 
peptide phage display. Cancer Letters. 
2001;171(2):153-64. 
7. Askoxylakis V, Zitzmann S, Mier W, Graham K, 
Krämer S, von Wegner F, et al. Preclinical evaluation 
of the breast cancer cell-binding peptide, p160. 
Clinical Cancer Research. 2005;11(18):6705-12. 
8. Soudy R, Gill A, Sprules T, Lavasanifar A, Kaur K. 
Proteolytically stable cancer targeting peptides with 
high affinity for breast cancer cells. Journal of 
Medicinal Chemistry. 2011;54(21):7523-34. 
9. Shahin M, Soudy R, El-Sikhry H, Seubert JM, Kaur 
K, Lavasanifar A. Engineered peptides for the 
development of actively tumor targeted liposomal 
carriers of doxorubicin. Cancer Letters. 
2013;334(2):284-92. 
10. Shahin M, Soudy R, Aliabadi HM, Kneteman N, 
Kaur K, Lavasanifar A. Engineered breast tumor 
targeting peptide ligand modified liposomal 
doxorubicin and the effect of peptide density on 
anticancer activity. Biomaterials. 2013;34(16):4089-
97. 
11. Bombelli C, Giansanti L, Luciani P, Mancini G. 
Gemini surfactant based carriers in gene and drug 
delivery. Current Medicinal Chemistry. 
2009;16(2):171-83. 
12. Wettig SD, Verrall RE, Foldvari M. Gemini 
surfactants: a new family of building blocks for non-
viral gene delivery systems. Current Gene Therapy. 
2008;8(1):9-23. 
13. Badea I, Verrall R, Baca‐Estrada M, Tikoo S, 
Rosenberg A, Kumar P, et al. In vivo cutaneous 
interferon‐γ gene delivery using novel dicationic 
(gemini) surfactant–plasmid complexes. The Journal 
of Gene Medicine. 2005;7(9):1200-14. 
14. Badea I. Gemini cationic surfactant-based delivery 
systems for non-invasive cutaneous gene therapy: 
University of Saskatchewan; 2006. 
15. Singh J, Michel D, Getson HM, Chitanda JM, Verrall 
RE, Badea I. Development of amino acid substituted 
gemini surfactant-based mucoadhesive gene delivery 
systems for potential use as noninvasive vaginal 
genetic vaccination. Nanomedicine. 2015;10(3):405-
17. 
16. Alqawlaq S, Sivak JM, Huzil JT, Ivanova MV, 
Flanagan JG, Beazely MA, et al. Preclinical 
development and ocular biodistribution of gemini-
DNA nanoparticles after intravitreal and topical 
administration: towards non-invasive glaucoma gene 
therapy. Nanomedicine: Nanotechnology, Biology 
and Medicine. 2014;10(8):1637-47. 
17. Mohammed-Saeid W, Chitanda J, Al-Dulaymi M, 
Verrall R, Badea I. Design and evaluation of RGD-
modified gemini surfactant-based lipoplexes for 
targeted gene therapy in melanoma model. 
Pharmaceutical Research. 2017;34(9):1886-96. 
18. Yang P, Singh J, Wettig S, Foldvari M, Verrall RE, 
Badea I. Enhanced gene expression in epithelial cells 
transfected with amino acid-substituted gemini 
nanoparticles. European Journal of Pharmaceutics 
and Biopharmaceutics. 2010;75(3):311-20. 
19. Michel D, Chitanda JM, Balogh R, Yang P, Singh J, 
Das U, et al. Design and evaluation of cyclodextrin-
based delivery systems to incorporate poorly soluble 
curcumin analogs for the treatment of melanoma. 
European Journal of Pharmaceutics and 
Biopharmaceutics. 2012;81(3):548-56. 
20. Al-Dulaymi MA, Chitanda JM, Mohammed-Saeid 
W, Araghi HY, Verrall RE, Grochulski P, et al. Di-
Peptide-Modified Gemini Surfactants as Gene 
Delivery Vectors: Exploring the Role of the Alkyl 
Tail in Their Physicochemical Behavior and 
Biological Activity. The AAPS journal. 2016:1-14. 
21. Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden 
VJ, Napier ME, et al. The effect of particle design on 
cellular internalization pathways. Proceedings of the 
National Academy of Sciences. 2008;105(33):11613-
8. 
22. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-
dependent internalization of particles via the 
pathways of clathrin-and caveolae-mediated 
endocytosis. Biochemical Journal. 2004;377(Pt 
1):159. 
23. Gene Therapy Clinical Trials Worldwide: John Wiley 
and Sons Ltd.; 2016 [cited 2012 25, April]. The 
Journal of Gene Medicine Clinical Trial site]. 
Available from: 
http://www.wiley.com//legacy/wileychi/genmed/clin
ical/. 
24. Harvie P, Dutzar B, Galbraith T, Cudmore S, 
O'Mahony D, Anklesaria P, et al. Targeting of lipid-
protamine-DNA (LPD) lipopolyplexes using RGD 
motifs. Journal of Liposome Research. 2003;13(3-
4):231-47. 
25. Bruckheimer E, Harvie P, Orthel J, Dutzar B, 
Furstoss K, Mebel E, et al. In vivo efficacy of folate-
targeted lipid–protamine–DNA (LPD-PEG-Folate) 
complexes in an immunocompetent syngeneic model 
for breast adenocarcinoma. Cancer Gene Therapy. 
2003;11(2):128-34. 
26. Surace C, Arpicco S, Dufaÿ-Wojcicki Al, Marsaud 
Vr, Bouclier Cl, Clay D, et al. Lipoplexes targeting 
the CD44 hyaluronic acid receptor for efficient 
transfection of breast cancer cells. Molecular 
Pharmaceutics. 2009;6(4):1062-73. 
J Pharm Pharm Sci (www.cspsCanada.org) 21, 363 - 375, 2018 
 
 
 
375 
27. Prabha S, Arya G, Chandra R, Ahmed B, Nimesh S. 
Effect of size on biological properties of 
nanoparticles employed in gene delivery. Artificial 
Cells, Nanomedicine, and Biotechnology. 
2016;44(1):83-91. 
28. Singh J, Michel D, Chitanda JM, Verrall RE, Badea 
I. Evaluation of cellular uptake and intracellular 
trafficking as determining factors of gene expression 
for amino acid-substituted gemini surfactant-based 
DNA nanoparticles. Journal of Nanobiotechnology. 
2012;10(1):7. 
29. Prabha S, Zhou W-Z, Panyam J, Labhasetwar V. 
Size-dependency of nanoparticle-mediated gene 
transfection: studies with fractionated nanoparticles. 
International Journal of Pharmaceutics. 
2002;244(1):105-15. 
30. Foldvari M, Badea I, Wettig S, Verrall R, Bagonluri 
M. Structural characterization of novel gemini non-
viral DNA delivery systems for cutaneous gene 
therapy. Journal of Experimental Nanoscience. 
2006;1(2):165-76. 
31. Kumar S, Zakrewsky M, Chen M, Menegatti S, 
Muraski JA, Mitragotri S. Peptides as skin 
penetration enhancers: mechanisms of action. Journal 
of Controlled Release. 2015;199:168-78. 
32. Moll R, Divo M, Langbein L. The human keratins: 
biology and pathology. Histochemistry and Cell 
Biology. 2008;129(6):705. 
33. Roth W, Kumar V, Beer H-D, Richter M, 
Wohlenberg C, Reuter U, et al. Keratin 1 maintains 
skin integrity and participates in an inflammatory 
network in skin through interleukin-18. Journal of 
Cell Science. 2012;125(22):5269-79. 
34. Soudy R, Etayash H, Bahadorani K, Lavasanifar A, 
Kaur K. Breast Cancer Targeting Peptide Binds 
Keratin 1: A New Molecular Marker for Targeted 
Drug Delivery to Breast Cancer. Molecular 
Pharmaceutics. 2017;14(3):593-604. 
35. Clauser KR, Hall SC, Smith DM, Webb JW, Andrews 
LE, Tran HM, et al. Rapid mass spectrometric peptide 
sequencing and mass matching for characterization of 
human melanoma proteins isolated by two-
dimensional PAGE. Proceedings of the National 
Academy of Sciences. 1995;92(11):5072-6. 
36. Hendrix MJ, Seftor EA, Chu Y-W, Seftor RE, Nagle 
RB, McDaniel KM, et al. Coexpression of vimentin 
and keratins by human melanoma tumor cells: 
correlation with invasive and metastatic potential. 
JNCI: Journal of the National Cancer Institute. 
1992;84(3):165-74. 
 
